Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Athenex stock
Own Athenex stock in just a few minutes.
Athenex, Inc is a drug manufacturers-specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 593 staff and has a trailing 12-month revenue of around USD$144.4 million.
How to buy shares in Athenex
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Athenex. Find the stock by name or ticker symbol: ATNX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Athenex reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Athenex, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Athenex. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Athenex share price
Use our graph to track the performance of ATNX stocks over time.Athenex shares at a glance
Information last updated 2021-04-15.
| 52-week range | USD$3.76 - USD$15.24 |
|---|---|
| 50-day moving average | USD$5.2139 |
| 200-day moving average | USD$10.5569 |
| Wall St. target price | USD$10.5 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.055 |
Buy Athenex shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Athenex stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Athenex financials
| Revenue TTM | USD$144.4 million |
|---|---|
| Gross profit TTM | USD$49 million |
| Return on assets TTM | -22.28% |
| Return on equity TTM | -87.01% |
| Profit margin | -101.24% |
| Book value | $1.925 |
| Market capitalisation | USD$392.5 million |
TTM: trailing 12 months
Shorting Athenex shares
There are currently 13.2 million Athenex shares held short by investors – that's known as Athenex's "short interest". This figure is 110.1% up from 6.3 million last month.
There are a few different ways that this level of interest in shorting Athenex shares can be evaluated.
Athenex's "short interest ratio" (SIR)
Athenex's "short interest ratio" (SIR) is the quantity of Athenex shares currently shorted divided by the average quantity of Athenex shares traded daily (recently around 6.1 million). Athenex's SIR currently stands at 2.16. In other words for every 100,000 Athenex shares traded daily on the market, roughly 2160 shares are currently held short.
However Athenex's short interest can also be evaluated against the total number of Athenex shares, or, against the total number of tradable Athenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athenex's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Athenex shares in existence, roughly 140 shares are currently held short) or 0.1808% of the tradable shares (for every 100,000 tradable Athenex shares, roughly 181 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Athenex.
Find out more about how you can short Athenex stock.
Athenex share dividends
We're not expecting Athenex to pay a dividend over the next 12 months.
Athenex share price volatility
Over the last 12 months, Athenex's shares have ranged in value from as little as $3.76 up to $15.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.6611. This would suggest that Athenex's shares are less volatile than average (for this exchange).
Athenex overview
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Frequently asked questions
More guides on Finder
-
How to buy ZTO Express Cayman stock
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
-
How to buy Zomedica stock
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
-
How to buy ZoomInfo Technologies stock
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
-
How to buy ZK International Group CoLtd stock
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
-
How to buy Zions Bancorporation National Association stock
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
-
How to buy ZIONL stock
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
-
How to buy Zentalis Pharmaceuticals stock
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong International stock
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
-
How to buy Zealand Pharma A/S stock
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong CTI stock
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
Ask an Expert